Two new photoactive metal-organic compounds for degradation of methylene blue and treatment in ophthalmic local anesthesia

J Fluoresc. 2022 May;32(3):1125-1133. doi: 10.1007/s10895-022-02911-8. Epub 2022 Mar 23.

Abstract

Two new metal-organic compounds, namely [Cu(CrO4)(4,4'-bipy)(H2O)]·n(H2O) (1) together with [Mn(Cr2O7)(bpp)2]n (2) (4,4'-bipy is 4,4'-bipyridine and bpp is 1,3-bis(4-pyridyl)propane), were hydrothermally generated, which were characterized structurally through a series of characterization techniques. Moreover, compounds 1 and 2 have 2.95 eV and 3.02 eV of narrow optical band gap values, and possess outstanding photocatalytic effects for the methylene blue degradation under irradiation of visible light. The application of above compounds in the ophthalmic local anesthesia was examined and the specific mechanism was tested. First of all, the acetylcholine content in the synaptic cleft was measured with enzyme linked immunosorbent assay (ELISA) assay after treated with the CPs. The acetylcholine receptor relative expression on nerve cells was subsequently measured via real time reverse transcription-polymerase chain reaction (RT-PCR) under the treatment of compounds. In the end, the complexes' toxicity was evaluated by Cell Counting Kit-8 (CCK-8) detection.

Keywords: Metal-organic compound; Ophthalmic local anesthesia; Photocatalysis.

MeSH terms

  • Anesthesia, Local*
  • Catalysis
  • Light
  • Metals
  • Methylene Blue* / pharmacology

Substances

  • Metals
  • Methylene Blue